Complement C4 Antibody Market Trends, Competitive Landscape and Future Growth

Complement C4 Antibody Market Size, Trends and Future Growth

The global complement C4 antibody market was estimated at US$ 19.21 billion in 2023 and is projected to grow to US$ 68.48 billion by 2034, rising at a compound annual growth rate (CAGR) of 12.25% from 2024 to 2034.

Key Takeaways

• North America dominated the global complement C4 antibody market in 2024.
• Asia Pacific is expected to be the fastest-growing during the forecast period.
• By type, the monoclonal antibodies segment dominated the market in 2024 and is estimated to be the fastest growing at a notable CAGR during the forecast period.
• By application type, the immunoassays segment dominated the market in 2024 and is anticipated to be the fastest growing during the forecast period.
•  By end user, the pharmaceutical & biotechnology companies segment dominated the global complement C4 antibody market in 2024.
• By end user, the diagnostic laboratories segment is predicted to be the fastest growing during the forecast period.

Market Overview

The complement C4 antibody market encompasses production, supply, research and development, and other aspects of complement C4 antibodies. These antibodies are developed for the complement C4, which is a component of the complement system. This system is an essential part of the immune response that kills pathogens, promotes inflammation, and enhances phagocytosis. The demand for antibodies is growing because researchers use antibodies to study the function of the complement system. These antibodies are also used for studying autoimmune diseases in which the complement system either regulates improperly or becomes overactive.

Complement C4 Antibody Market Trends

• In August 2024, for the purpose of reducing proteinuria in people with primary immunoglobulin A nephropathy (IgAN) who are at risk of fast disease progression, Novartis announced that the U.S. Food and Drug Administration (FDA) has given expedited clearance for Fabhalta® (iptacopan), a first-in-class complement inhibitor.
• In May 2024, Commit Biologics, a leader in the use of complement system activation for the treatment of autoimmune diseases and cancer, emerged from stealth today with €16 million in seed investment from Novo Holdings and Bioqube Ventures.

Market Dynamics

Rising Number of Autoimmune Diseases Creates Growth Opportunity

Autoimmune is a rising concern and needs attention from researchers and the healthcare system to provide better treatment options. The growing cases of autoimmune diseases create growth opportunities for the complement C4 antibody market because the market provides an opportunity for developing better treatment options.

Complementing C4 antibodies is essential in researching and diagnosing autoimmune conditions. The antibodies are used in understanding the role of the complement system in autoimmune diseases. The growing need for the complement C4 antibodies demands investments and innovation in the sector.

Challenge: High Research & Development Cost

Production of complement C4 antibodies is a complex process that is expensive and time-consuming. During research, extensive lab work is done, which includes protein purification, culturing cells, and validation studies, which further increases the cost. A further cost is added due to the need for advanced technology, equipment, and skilled professionals. These costs can become a significant barrier for start-ups or smaller companies that are looking to enter the market.

Regional Insights

North America Dominated the complement C4 antibody market in 2023. North America has a strong presence of key market players that collaborate with government organizations and other key players to conduct research and development. Apart from this complement, C4 antibodies are used by pharmaceutical and biotechnology companies for various purposes, and North America dominates in both sectors.

The U.S. held the largest share of the complement C4 antibody market in North America. The country strongly invests in research and development, developing new treatment options and other aspects of healthcare. Apart from this, there is a growing prevalence of autoimmune diseases in the U.S. According to the National Institute of Environmental Health Sciences, around 50 million people in the U.S. have an autoimmune disease. This makes autoimmune disease the third most prevalent disease category. The government and other organizations are making efforts in R&D and improvement of autoimmune disease treatment.

For instance,

• The U.S. Congress instructed NIH to create an Office of Autoimmune Disease Research under ORWH in 2022 in order to expedite advancements in this field. OADR-ORWH's establishment within the NIH Office of the Director (OD) puts it in a strong position to foster chances for group innovation while amplifying and integrating individual ICO efforts. Supporting high-priority autoimmune disease research, spotting new avenues for innovation, and encouraging cooperation between NIH ICOs are the goals of OADR-ORWH.

Asia Pacific is expected to grow at the fastest rate during the forecast period. The complement C4 antibody market is growing in Asia Pacific because of growing government investments in research and development and the improvement of the healthcare system. China, India, Japan, and South Korea are the countries that majorly contribute to the market's growth. There is growing research in these countries related to autoimmune diseases.

For instance,

• In August 2024, Funding for the development of a quick and precise diagnostic tool for the early detection of autoimmune illnesses, including lupus and arthritis, was provided by the Ministry of Science and Technology (MOST) of China and the Department of Science and Technology (DOST) of the Philippines.

The government of India formed the National Consortium for Research and Development on Therapeutics for Rare Illnesses to encourage collaboration in the field of rare disease research and development for the purpose of diagnosing and treating rare illnesses in the country. A number of autoimmune disorders fall under the uncommon disease umbrella.

Europe is expected to grow significantly in the complement C4 antibody market during the forecast period. The industries in Europe are developing various new treatment options for different diseases using the complement C4 antibody. The rising occurrences of cancer, as well as other diseases, are increasing the use of complement C4 antibody treatment options. This further drives the production process. The innovation carried out using the complement C4 antibody for developing new treatment approaches in the industries of German industry contributes to the market growth.

Segmental Insights

By type, the monoclonal antibodies segment dominated the complement C4 antibody market and is expected to grow with the fastest CAGR during the forecast period. One of the most effective biologics for a range of uses is monoclonal antibodies. These compounds have great selectivity, specificity, and binding affinity, which are usually reasons to use them. Furthermore, the majority of monoclonal antibodies may be readily made in recombinant systems and have well-defined sequences, affinities, and other characteristics. Strong batch-to-batch consistency and excellent purity are ensured by producing these reagents in specified systems and media, which is crucial for many applications.

By application, the immunoassays segment held the largest complement C4 antibody market share in 2023 and is expected to grow rapidly during the forecast period. Applications for complement C4-detecting antibodies in science include immunohistochemistry, ELISA, and immunoprecipitation. Complement C4 is the target of these antibodies in samples from humans, mice, and rats. With the aid of complement C4 antibodies, immunoassays are utilized to discover health problems. A patient with symptoms suggestive of an accident, recent infection, or autoimmune illness may be advised to undergo the complement C4 test by their physician.

By end-user, the pharmaceutical & biotechnology companies segment showcased its dominance over the market in 2023. These companies use complement C4 antibodies for research and development, or developing diagnostic kits, and development of better treatment options. By end-user, the diagnostic laboratories are estimated to grow at the fastest CAGR in the complement C4 antibody market during the predicted timeframe. Complement C4 antibodies are used to conduct C4 complement tests. These tests are conducted in diagnostic laboratories for the detection of autoimmune disorders, injuries, or recent infections.

Recent Developments

• In May 2025, a fast-track designation was granted for a new drug, ISB 2001, used for the treatment of multiple Myeloma by the US Food and Drug Administration (FDA) to Ichnos Glenmark Innovation, the arm of Glenmark Pharmaceuticals' research and innovation. Being an investigational trispecific antibody therapeutic, it targets BCMA and CD38 on myeloma cells and CD3 on T cells.
• In May 2025, in the POTOMAC Phase III trial, a human monoclonal antibody, Imfinzi (durvalumab), developed by AstraZeneca, was merged with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, which showed improvement in individuals with high-risk non-muscle-invasive bladder cancer (NMIBC), contributing to the disease-free survival (DFS).
• In August 2024, monoclonal antibodies produced by CU School of Medicine identify complement system proteins that are activated on injured tissues as opposed to blood vessels.
• In June 2023, in the latest work, scientists used bispecific single-domain antibodies, or BiCEs, to create a way to activate the complement system. The complement protein C1q and a particular protein found on the surface of cancer cells are the two distinct targets to which these antibodies can bind simultaneously. The findings were published in The Journal of Immunology. Through the interaction of BiCE molecules with the cancer cell protein and C1q, the complement system can be potently activated, resulting in the targeted cancer cells' selective destruction.

Top Companies in the Complement C4 Antibody Market

• AbbVie
• Amgen
• 3M
• Pfizer
• Roche
• Merck
• AstraZeneca
• Novartis
• Eli Lily and Company
• Celgene
• Bayer
• GlaxoSmithKline
• Bristol-Myers Squibb

Segments Covered in the Report

By Type

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Antibodies
• Antibody Fragments

By Application

• Immunoassays
• Western Blotting
• Immunohistochemistry
• Flow Cytometry

By End-User

• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Academic & Research Institutions
• Clinical Laboratories

By Region

• North America 
  
  • U.S.
  • Canada
• Asia Pacific 
  
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe 
  
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America 
  
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA) 
  
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait